The FDA’s updated clinical decision support (CDS) software guidance reinforces existing expectations while making the agency’s position clearer than ever. Rather than introducing new rules, it confirms how CDS should be evaluated within FDA inspections in clinical trials, with important implications for IRB oversight and study design.
This article reviews:
- What has and hasn’t changed in FDA CDS guidance, including a stronger stance on classification and oversight expectations
- Why concepts like automation bias and independent clinician review remain central to evaluating CDS risk
- What sponsors, CROs, investigators, and IRBs should be prepared to demonstrate to support inspection readiness and clinical research compliance
For research teams, the message is simple: transparency around how CDS tools function and how they influence decision-making is essential to both ethical review and regulatory alignment.
Read the full article on Clinical Leader for the complete picture.
